Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
VENN BIOSCIENCES CORPORATION has 2 pending office actions in the Chemistry & Materials technology area. These 2 actions are assigned to 2 distinct examiners, but both are located within 1 distinct art unit. This concentration in a single art unit suggests that the company's current filings are technically related and fall under the same specialized group's review.
FRANK, RODNEY T is the busiest examiner with 1 busiest examiner pending action. With 2 pending office actions and 2 distinct examiners, the workload is evenly distributed, with no single examiner handling more than one case. However, the fact that both examiners are in 1 distinct art unit means the company can maintain a consistent technical approach for both applications. Practitioners should focus on the specific standards of this art unit while also accounting for the individual styles of the 2 distinct examiners. This structure allows for a relatively unified prosecution strategy in the Chemistry & Materials field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRANK, RODNEY T | 1 | 72.7% | +3.6% |
| XU, XIAOYUN | 1 | 60.0% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18180789 | IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND TREATMENT MONITORING | XU, XIAOYUN | 28d |
| 18840561 | SAMPLE PREPARATION FOR GLYCOPROTEOMIC ANALYSIS THAT INCLUDES DIAGNOSIS OF DISEASE | FRANK, RODNEY T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18180789 | IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND TREATMENT MONITORING | XU, XIAOYUN | 28d |
| Art Unit | Apps |
|---|---|
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840561 | SAMPLE PREPARATION FOR GLYCOPROTEOMIC ANALYSIS THAT INCLUDES DIAGNOSIS OF DISEASE | FRANK, RODNEY T | — | §103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18180789 | IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND TREATMENT MONITORING | XU, XIAOYUN | 1797 | §102§103Other | Final Rejection | 28d | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial